Roivant Sciences (ROIV) Other financing activities (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Other financing activities came in at $1.2 million in Q4 2025, down 96.88% YoY from $37.0 million in Q4 2024, and up 103.94% on a QoQ basis from -$29.3 million in Q3 2025.
Roivant Sciences (ROIV) Other financing activities (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 4 years of Other financing activities data on file, last reported at $1.2 million in Q4 2025.
- Quarterly Other financing activities fell 96.88% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $38.9 million (down 59.83% YoY) and the FY2025 annual result came in at $49.6 million, up 991840.0% from the prior year.
- Other financing activities advanced to $1.2 million in Q4 2025, from -$29.3 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $51.0 million in Q4 2023 to a low of -$29.3 million in Q3 2025.
- A 3-year average of $11.0 million and a median of $6.6 million in 2024 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 1223.51% in 2025, down 542.34% in 2025.
- Tracing ROIV's Other financing activities over 3 years: stood at $51.0 million in 2023, then dropped by 27.47% to $37.0 million in 2024, then tumbled by 96.88% to $1.2 million in 2025.
- The last three Other financing activities figures came in at $1.2 million (Q4 2025), -$29.3 million (Q3 2025), and $30.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76.02 Mn |
| Jun 30, 2026 | 76.02 Mn |
| Dec 31, 2025 | 1.16 Mn |
| Dec 31, 2025 | 1.16 Mn |
| Sep 30, 2025 | -29.28 Mn |
| Sep 30, 2025 | -29.28 Mn |
| Jun 30, 2025 | 30.06 Mn |
| Jun 30, 2025 | 30.06 Mn |
| Dec 31, 2024 | 37.01 Mn |
| Dec 31, 2024 | 37.01 Mn |
| Sep 30, 2024 | 6.62 Mn |
| Sep 30, 2024 | 6.62 Mn |
| Jun 30, 2024 | 2.27 Mn |
| Jun 30, 2024 | 2.27 Mn |
| Dec 31, 2023 | 51.02 Mn |
| Dec 31, 2023 | 51.02 Mn |
| Sep 30, 2023 | -20.44 Mn |
| Sep 30, 2023 | -20.44 Mn |
| Jun 30, 2023 | 21.03 Mn |
| Jun 30, 2023 | 21.03 Mn |